Home › Calculator › PVCT Dividend Calculator 2026
PVCT Dividend DRIP Calculator 2026
2906.98% YieldHealthcareProvectus Biopharmaceuticals, Inc. · OTC
Price: $0.07 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When PVCT pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your PVCT snowball 📈
$10,000 in PVCT → $6043669308298.03M in 10 years · $486,890,089,931,202,560.00/month
About Provectus Biopharmaceuticals, Inc. (PVCT) — Dividend Analysis 2026
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Compare PVCT with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full PVCT DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open PVCT position with:
🌍 PVCT Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold PVCT.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2906.98% | 2904.18% | $290,698 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2470.93% | 2468.13% | $247,093 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2325.58% | 2322.78% | $232,558 / yr |
| 🇬🇧 UK ISA | 0% | 2906.98% | 2904.18% | $290,698 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2652.62% | 2649.82% | $265,262 / yr |
| 🇨🇦 TFSA | 0% | 2906.98% | 2904.18% | $290,698 / yr |
| 🇨🇦 CA Taxable | 25% | 2180.24% | 2177.43% | $218,024 / yr |
| 🇦🇺 Super (pension) | 15% | 2470.93% | 2468.13% | $247,093 / yr |
| 🇦🇺 AU Taxable | 30% | 2034.89% | 2032.09% | $203,489 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2140.26% | 2137.46% | $214,026 / yr |
| 🇫🇷 FR Taxable | 30% | 2034.89% | 2032.09% | $203,489 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 PVCT Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 PVCT Dividend Payment Schedule
PVCT pays quarterly — 4 times per year. Next ex-div: TBD.
📊 PVCT vs Healthcare Benchmarks
How PVCT compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PVCT sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ PVCT Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-30 | 45,860 | — | — | ||
| A-Award | 2026-06-30 | 45,860 | — | — | ||
| A-Award | 2026-06-30 | 48,917 | — | — | ||
| A-Award | 2026-06-30 | 48,917 | — | — | ||
| M-Exempt | 2026-06-05 | 9,436 | — | — | ||
| M-Exempt | 2026-05-23 | 32,089 | — | — | ||
| M-Exempt | 2026-05-15 | 22,651 | — | — | ||
| M-Exempt | 2026-05-07 | 18,876 | — | — | ||
| M-Exempt | 2026-04-29 | 30,202 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PVCT dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Provectus Biopharmaceuticals, Inc. (PVCT) is currently trading at $0.07, 65% below its 52-week high. The current dividend yield is 2906.98% based on an annual payout of $2.00 per share.
PVCT (Provectus Biopharmaceuticals, Inc.) — 2906.98% Dividend Yield Analysis
Provectus Biopharmaceuticals, Inc. (PVCT) is a healthcare stock currently trading at $0.07 with a dividend yield of 2906.98%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (2906.98%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.